Alison
Banham
Key publications
-
FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. Journal article Brown PJ. et al, (2016), Leukemia, 30, 605 - 616 -
The European antibody network's practical guide to finding and validating suitable antibodies for research. Journal article Roncador G. et al, (2016), MAbs, 8, 27 - 36 -
A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Journal article Masiero M. et al, (2013), Cancer Cell, 24, 229 - 241
Recent publications
-
Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration. Journal article Giatromanolaki A. et al, (2020), Br J Cancer -
CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model. Journal article Felce SL. et al, (2020), Front Oncol, 10 -
ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile. Journal article Favara DM. et al, (2019), Metabolites, 9 -
Development of therapeutic anti-JAGGED1 antibodies for cancer therapy. Journal article Masiero M. et al, (2019), Mol Cancer Ther -
ADGRL4/ELTD1 is a highly conserved angiogenesis-associated orphan adhesion GPCR that emerged with the first vertebrates and comprises 3 evolutionary variants. Journal article Favara DM. et al, (2019), BMC Evol Biol, 19